Epidermal growth factor receptor inhibition and non-small cell lung cancer (Q36504349)

14 August 2017

1 reference

title

Epidermal growth factor receptor inhibition and non-small cell lung cancer (English)

1 reference

14 August 2017

1 reference

Finn Edler von Eyben

1

1 reference

14 August 2017

publication date

1 January 2006

1 reference

Critical Reviews in Clinical Laboratory Sciences

14 August 2017

published in

1 reference

14 August 2017

volume

43

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

291-323

1 reference

Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

The ErbB/HER receptor protein-tyrosine kinases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

The ErbB receptors and their role in cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Quantitative PCR--new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

PI3K-Akt pathway: its functions and alterations in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

EGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Targeting the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Molecular therapy of head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Monoclonal antibodies targeting the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Mechanism of action of erbB tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Structural alterations of the epidermal growth factor receptor gene in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Radiation combined with EGFR signal inhibitors: head and neck cancer focus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Coamplification and coexpression of GRB7 and ERBB2 is found in high grade intraepithelial neoplasia and in invasive Barrett's carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Somatic mutations of epidermal growth factor receptor in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

The epidermal growth factor receptor as a target for gastrointestinal cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: protein overexpression, gene amplification and activation of downstream molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Lung cancer: intragenic ERBB2 kinase mutations in tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

The role of HER2/neu expression and trastuzumab in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Current management of advanced non-small cell lung cancer: targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Are more aggressive therapies able to improve treatment of locally advanced non-small cell lung cancer: combined modality treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Severe acute interstitial pneumonia and gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

EGFR tyrosine kinase inhibitors in non-small cell lung cancer: report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Benign lesions in cancer patients: Case 1. Sarcoidosis after chemoradiation for head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Predictors of the response to gefitinib in refractory non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Additive interaction of gefitinib ('Iressa', ZD1839) and ionising radiation in human tumour cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

EGFR and erbB2 mutation status in Japanese lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

Mutations of epidermal growth factor receptor andK-rasgenes in adenosquamous carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10408360600728369

10.1080/10408360600728369

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference